Genentech owns a patent on tissue plasminogen activator (TPA), which is an enzyme that helps the body break down blood clots. TPA is particularly valuable to cardiac patients since it often allows heart problems to be treated with medication rather than surgery. Recently, however, firms in the medical industry have come under fire by some members of Congress and the press for charging high prices and earning monopoly profits. Do you think cardiac patients would benefit if the government stripped Genentech and other pharmaceutical firms of their patents?

Answer rating: 100% (QA)

The monopoly profits earned by Genentech are its benefit and reward for increasing ... View the full answer